SKYE (Skye Bioscience Inc.) Market Value to Book Value Ratio

Skye Bioscience, Inc. (SKYE) develops innovative cannabinoid-based medicines to combat metabolic disorders and glaucoma. This biotech segment demonstrates high macroeconomic resilience and is unaffected by seasonality or cycles, as success depends on the results of medical trials. The current indicator is -13.85. To optimize processes, the company utilizes external laboratories while maintaining full patent control. This chart illustrates the asset's price trend.

Institutional interest in Skye Bioscience, Inc. (SKYE) is driven by a market value premium over net assets, reflecting capital's confidence in the intellectual potential of the cannabinoid drug developer. By analyzing changes in the price-to-book multiple, investors assess the ratio of market capitalization to book value, where the absence of large-scale manufacturing plants shifts the focus from tangible resources to intangible value and the reliability of the business model.